Results 61 to 70 of about 15,372 (163)
Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer
Background Ropivacaine, a local anesthetic, exhibits anti-tumor effects in various cancer types. However, its specific functions and the molecular mechanisms involved in breast cancer cell stemness remain elusive.
Lin Ding +11 more
doaj +1 more source
Study objectiveRecent studies have shown that dexmedetomidine can be safely used in peripheral nerve blocks and spinal anesthesia. Epidural administration of dexmedetomidine produces analgesia and sedation, prolongs motor and sensory block time, extends ...
Ji-Xiang Wan +5 more
doaj +1 more source
Background: Ropivacaine is a common choice for supraclavicular brachial plexus block. Dexmedetomidine and Dexamethasone are frequently added to local anesthetics for improved effects.
Kumud Pyakurel +2 more
doaj +3 more sources
Background: Postoperative discomfort subsequent to a caesarean delivery significantly influences the recuperation process and necessitates efficacious therapeutic intervention.
Ahmad Habibi Siregar +3 more
doaj +1 more source
Lili Wu, Chunhua Xi, Guiyu Lei, He Li, Yue Yin, Meixuan Wan, Haiyao Wu, Yue Wang, Chunhua Hu, Guyan Wang Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence: Guyan Wang ...
Wu L +9 more
doaj
Ropivacaine is a commonly used local anesthetic for brachial plexus blocks in children, but the minimum effective dose of ropivacaine for interscalene brachial plexus blocks has not been reported.
Li Yang +7 more
doaj +1 more source
Background: Epidural anesthesia is a neuraxial regional anesthesia used to provide surgical anesthesia, to supplement general anesthesia, and to provide intra and post-operative analgesia.
Shreya Putta +3 more
doaj +1 more source
Butorphanol decreased the median effective concentration of ropivacaine in ultrasound-guided interscalene brachial plexus block. [PDF]
Su H, Li J, Zhang J, Zhang Y, Tu F.
europepmc +1 more source

